These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 16998799

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Disruption of the MYC transcriptional function by a small-molecule antagonist of MYC/MAX dimerization.
    Lu X, Vogt PK, Boger DL, Lunec J.
    Oncol Rep; 2008 Mar; 19(3):825-30. PubMed ID: 18288422
    [Abstract] [Full Text] [Related]

  • 3. Elucidation of the structural determinants responsible for the specific formation of heterodimeric Mxd1/Max b-HLH-LZ and its binding to E-box sequences.
    Montagne M, Naud JF, Lavigne P.
    J Mol Biol; 2008 Feb 08; 376(1):141-52. PubMed ID: 18155722
    [Abstract] [Full Text] [Related]

  • 4. myc, max, and a novel rlf-L-myc fusion protein in small-cell lung cancer.
    Västrik I, Mäkelä TP, Koskinen PJ, Saksela K, Alitalo K.
    Princess Takamatsu Symp; 1991 Feb 08; 22():307-18. PubMed ID: 1668890
    [Abstract] [Full Text] [Related]

  • 5. Upstream stimulatory factor (USF) as a transcriptional suppressor of human telomerase reverse transcriptase (hTERT) in oral cancer cells.
    Chang JT, Yang HT, Wang TC, Cheng AJ.
    Mol Carcinog; 2005 Nov 08; 44(3):183-92. PubMed ID: 16010690
    [Abstract] [Full Text] [Related]

  • 6. Synergistic induction of the Fas (CD95) ligand promoter by Max and NFkappaB in human non-small lung cancer cells.
    Wiener Z, Ontsouka EC, Jakob S, Torgler R, Falus A, Mueller C, Brunner T.
    Exp Cell Res; 2004 Sep 10; 299(1):227-35. PubMed ID: 15302589
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of cancer cell growth and c-Myc transcriptional activity by a c-Myc helix 1-type peptide fused to an internalization sequence.
    Giorello L, Clerico L, Pescarolo MP, Vikhanskaya F, Salmona M, Colella G, Bruno S, Mancuso T, Bagnasco L, Russo P, Parodi S.
    Cancer Res; 1998 Aug 15; 58(16):3654-9. PubMed ID: 9721875
    [Abstract] [Full Text] [Related]

  • 8. Insights into the mechanism of heterodimerization from the 1H-NMR solution structure of the c-Myc-Max heterodimeric leucine zipper.
    Lavigne P, Crump MP, Gagné SM, Hodges RS, Kay CM, Sykes BD.
    J Mol Biol; 1998 Aug 07; 281(1):165-81. PubMed ID: 9680483
    [Abstract] [Full Text] [Related]

  • 9. Low molecular weight inhibitors of Myc-Max interaction and function.
    Yin X, Giap C, Lazo JS, Prochownik EV.
    Oncogene; 2003 Sep 18; 22(40):6151-9. PubMed ID: 13679853
    [Abstract] [Full Text] [Related]

  • 10. Mouse Sin3A interacts with and can functionally substitute for the amino-terminal repression of the Myc antagonist Mxi1.
    Rao G, Alland L, Guida P, Schreiber-Agus N, Chen K, Chin L, Rochelle JM, Seldin MF, Skoultchi AI, DePinho RA.
    Oncogene; 1996 Mar 07; 12(5):1165-72. PubMed ID: 8649810
    [Abstract] [Full Text] [Related]

  • 11. The Max homodimeric b-HLH-LZ significantly interferes with the specific heterodimerization between the c-Myc and Max b-HLH-LZ in absence of DNA: a quantitative analysis.
    McDuff FO, Naud JF, Montagne M, Sauvé S, Lavigne P.
    J Mol Recognit; 2009 Mar 07; 22(4):261-9. PubMed ID: 19189276
    [Abstract] [Full Text] [Related]

  • 12. New structural determinants for c-Myc specific heterodimerization with Max and development of a novel homodimeric c-Myc b-HLH-LZ.
    Beaulieu ME, McDuff FO, Frappier V, Montagne M, Naud JF, Lavigne P.
    J Mol Recognit; 2012 Jul 07; 25(7):414-26. PubMed ID: 22733550
    [Abstract] [Full Text] [Related]

  • 13. Decreased tumorigenicity of c-Myc-transformed fibroblasts expressing active USF2.
    Choe C, Chen N, Sawadogo M.
    Exp Cell Res; 2005 Jan 01; 302(1):1-10. PubMed ID: 15541720
    [Abstract] [Full Text] [Related]

  • 14. c-Myc creates an activation loop by transcriptionally repressing its own functional inhibitor, hMad4, in young fibroblasts, a loop lost in replicatively senescent fibroblasts.
    Marcotte R, Chen JM, Huard S, Wang E.
    J Cell Biochem; 2005 Dec 01; 96(5):1071-85. PubMed ID: 16167342
    [Abstract] [Full Text] [Related]

  • 15. Identification of casein kinase II phosphorylation sites in Max: effects on DNA-binding kinetics of Max homo- and Myc/Max heterodimers.
    Bousset K, Henriksson M, Lüscher-Firzlaff JM, Litchfield DW, Lüscher B.
    Oncogene; 1993 Dec 01; 8(12):3211-20. PubMed ID: 8247525
    [Abstract] [Full Text] [Related]

  • 16. Both the helix-loop-helix and the leucine zipper motifs of c-Myc contribute to its dimerization specificity with Max.
    Davis LJ, Halazonetis TD.
    Oncogene; 1993 Jan 01; 8(1):125-32. PubMed ID: 8423990
    [Abstract] [Full Text] [Related]

  • 17. Mnt transcriptional repressor is functionally regulated during cell cycle progression.
    Popov N, Wahlström T, Hurlin PJ, Henriksson M.
    Oncogene; 2005 Dec 15; 24(56):8326-37. PubMed ID: 16103876
    [Abstract] [Full Text] [Related]

  • 18. Lack of correlation between N-myc and MAX expression in neuroblastoma tumors and in cell lines: implication for N-myc-MAX complex formation.
    Raschella G, Romeo A, Negroni A, Pucci S, Dominici C, Castello MA, Bevilacqua P, Felsani A, Calabretta B.
    Cancer Res; 1994 Apr 15; 54(8):2251-5. PubMed ID: 8174135
    [Abstract] [Full Text] [Related]

  • 19. Direct visualization of the binding of c-Myc/Max heterodimeric b-HLH-LZ to E-box sequences on the hTERT promoter.
    Lebel R, McDuff FO, Lavigne P, Grandbois M.
    Biochemistry; 2007 Sep 11; 46(36):10279-86. PubMed ID: 17705400
    [Abstract] [Full Text] [Related]

  • 20. Loss of the Max-interacting protein Mnt in mice results in decreased viability, defective embryonic growth and craniofacial defects: relevance to Miller-Dieker syndrome.
    Toyo-oka K, Hirotsune S, Gambello MJ, Zhou ZQ, Olson L, Rosenfeld MG, Eisenman R, Hurlin P, Wynshaw-Boris A.
    Hum Mol Genet; 2004 May 15; 13(10):1057-67. PubMed ID: 15028671
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.